Adrian was external examiner for a PhD candidate at the brain imaging center of the University of Lyon, France (11th December 2013). The thesis work was carried out by Guillaume Becker, in the laboratory of Prof. Luc Zimmer. The thesis was entitled: "New concepts for functional imaging of serotonin 5-HT1A and 5-HT6 receptors during neurodegenerative processes."
Lecture at Pharmacology 2013 meeting in London
Adrian Newman-Tancredi was an invited speaker at the British Pharmacological Society'smeeting on Tuesday 17 December. The session was organized by theInternational Society for Serotonin Research, of which Adrian is European Council member, and presented recent discoveries that bring renewed interest in serotonin receptors as promising targets for treatment of psychiatric and neurological disorders. For further information click here.
Neurolixis Update
European Commission approves Orphan Medicinal Product designation for NLX-101
Neurolixis Inc., of which Adrian Newman-Tancredi, PhD, DSc, is co-founder and Chief Scientific Officer, announced that the European Commission approved its application for Orphan Medicinal Product Designation for NLX-101 in the treatment of Rett syndrome (see European Commission register). Rett syndrome is a rare genetic disorder that affects 1 female in about 10 000 and causes extensive and debilitating symptoms. NLX-101 targets the breathing difficulties that are commonly experienced by Rett syndrome patients. Orphan Medicinal Product designation provides a ten-year period of European Union marketing exclusivity as well as other benefits.
Adrian Newman-Tancredi is Principal Investigator of a supplemental grant awarded by the Michael J Fox Foundation. The grant will support investigation of a highly selective serotonin 5-HT1A receptor agonist, NLX-112, in models of Parkinson's Disease. The experiments will be carried out in collaboration with Dr. Andrew McCreary of BrainsOnline (Groningen, Netherlands).
NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.
NeuroAct Communicationis an independent consulting service founded by
Adrian Newman-Tancredi PhD DSc, an experienced pharmaceutical industry professional. Find out more about Adrian in hisExecutive Profile
